Feature | January 16, 2013

First U.S. Patient Treated with Cook Medical’s Zilver PTX Drug-Eluting Peripheral Stent

Ohio hospital is first to use Zilver PTX stent commercially

January 16, 2013 — Just weeks after the Food and Drug Administration (FDA) approved Cook Medical’s Zilver PTX drug-eluting peripheral stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook’s U.S. commercial launch.

“It was a great honor for my institution to be first to implant Cook Medical’s Zilver PTX as part of the stent’s commercial roll-out,” said Gary Ansel, M.D., director for the Center for Critical Limb Care at Riverside Methodist Hospital. “This technology is so advanced and offers such prolonged patient benefit, I believe it will very quickly challenge older PAD treatments such as balloon angioplasty and bare metal stenting in the U.S. as the standard of PAD care.”

Zilver PTX, approved for use in the above-the-knee femoropopliteal artery, is the only drug-eluting stent approved for use in a peripheral artery in the U.S. The device reduces by more than 50 percent the need for follow-up procedures to reopen the artery. These follow-up procedures can be expensive, which places extra burdens on patients, physicians and facilities.

This combination therapy device combines the mechanical support of stenting with the drug paclitaxel, which limits cell growth that can reclog the artery. The combination has been shown to maintain arterial blood flow to the superficial femoral artery (SFA) in seven out of 10 patients through 24 months after implantation.

The disease Zilver PTX targets, peripheral arterial disease (PAD), is one of the fastest-growing and most pervasive diseases of our time, affecting an estimated 8-12 million Americans each year. PAD is a disease in which plaque builds up in the arteries, which carry blood to the head, organs and limbs. While PAD typically affects arteries in the legs, it can also affect blood flow to the head, arms, kidneys and stomach. People aged 50 and over who have a history of diabetes, smoking and high blood pressure are at higher risk for PAD.

Other treatment modalities for PAD include medical management, lifestyle changes such as exercise, balloon angioplasty, bare metal stenting and surgical bypass of the blocked artery.

For more information: www.cookmedical.com

Related Content

Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
Absorb, bioresorbable stents
Feature | Stents Bioresorbable| April 13, 2016 | Dave Fornell
Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings ov
PinnacleHealth Cardiovascular Institute, TOBA II study, first patient, Tack Endovascular System, PAD
News | Peripheral Arterial Disease (PAD)| March 22, 2016
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania into the TOBA II clinical on Oct. 19...
Boston Scientific, Eluvia vascular stent system, CE Mark, peripheral artery disease
News | Stents Peripheral| March 17, 2016
Boston Scientific announced in late February that the Eluvia Drug-Eluting Vascular Stent System received CE Mark, and...
Biotronik, BIOSCIENCE trial, Orsiro hybrid DES, drug-eluting stent, STEMI heart attack patients
News | Stents Drug Eluting| March 07, 2016
Biotronik announced publication of results from the BIOSCIENCE trial in the journal EuroIntervention. The study’s...
Intact Vascular, Tack Endovascular System

The Intact Vascular Tack Endovascular System is designed to spot stent dissections with a short, self-expanding 6 mm long stent that can expand to vessel diameters between 2.5-6 mm, so exact sizing is not needed.

Feature | Peripheral Arterial Disease (PAD)| February 22, 2016 | Dave Fornell
It is estimated that more than 10 million people in the United States are affected by...
peripheral stents, market report 2020, MedMarket Diligence
News | Stents Peripheral| February 19, 2016
Peripheral stents will account for over $4.6 billion in worldwide sales by 2020, according to a new report from...
Biotronik, Maquet, partnership, peripheral vascular devices, U.S. market, Astron self-expanding iliac stent
Technology | Stents Peripheral| February 17, 2016
Biotronik announced a partnership with Maquet Medical Systems USA to distribute Biotronik peripheral vascular devices...
Stentys, commercialization, BTK stent, below-the-knee arteries
News | Stents Peripheral| February 08, 2016
Stentys announced the first distribution agreements for its drug-eluting stent for treating below-the-knee (BTK)...
Overlay Init